

Can't fill your Tenofovir Alafenamide (Vemlidy) prescription? Learn about real alternatives for chronic hepatitis B, including Entecavir and TDF.
If you've been prescribed Tenofovir Alafenamide (brand name Vemlidy) for chronic hepatitis B and can't find it at your pharmacy, you're probably wondering: What are my options?
Missing your antiviral medication isn't something to take lightly. Hepatitis B requires consistent treatment, and gaps in therapy can lead to serious complications — including a severe flare-up of the virus. The good news is that there are legitimate alternative medications your doctor can consider.
In this post, we'll explain what Tenofovir Alafenamide is, how it works, and walk through real alternatives that your healthcare provider may prescribe if you can't access it.
Tenofovir Alafenamide (TAF) is an antiviral medication manufactured by Gilead Sciences. It's FDA-approved for treating chronic hepatitis B virus (HBV) infection in adults and children ages 6 and older weighing at least 25 kg with compensated liver disease.
Sold as Vemlidy, it comes as a 25 mg tablet taken once daily with food. It's also a key ingredient in several HIV combination products including Descovy, Biktarvy, Genvoya, and Odefsey.
For a complete overview, read our post on what Tenofovir Alafenamide is and what you need to know.
Tenofovir Alafenamide belongs to a class of drugs called nucleotide reverse transcriptase inhibitors (NtRTIs). Here's how it works in simple terms:
TAF is actually a newer, improved version of an older drug called Tenofovir Disoproxil Fumarate (TDF). TAF delivers the active drug more efficiently at a much lower dose, which means fewer side effects — particularly on kidneys and bones.
For a more detailed explanation, see how Tenofovir Alafenamide works: mechanism of action explained.
If you can't fill your Tenofovir Alafenamide prescription, these are the most commonly prescribed alternatives. Always talk to your doctor before switching medications — they'll consider your viral load, liver function, treatment history, and other health conditions.
Tenofovir Disoproxil Fumarate is the most direct alternative to Tenofovir Alafenamide. Both are prodrugs of tenofovir — they deliver the same active ingredient to fight hepatitis B.
TDF is often the first medication insurance companies require through step therapy before approving Vemlidy.
Entecavir is a nucleoside analog that's considered a first-line treatment for chronic hepatitis B alongside tenofovir-based drugs.
Lamivudine is one of the oldest antiviral medications for hepatitis B. While it's effective, it has a significant drawback: high resistance rates with long-term use.
Adefovir is an older nucleotide analog that's rarely used as a first-line treatment today. It's less potent than Tenofovir Alafenamide and has more kidney-related side effects.
Tenofovir Alafenamide carries a boxed warning — the most serious type of FDA warning — about what can happen if you stop taking it suddenly. Discontinuing anti-hepatitis B therapy can trigger severe acute exacerbations of hepatitis B, which can be life-threatening.
If you can't find your medication:
While Tenofovir Alafenamide (Vemlidy) is an excellent medication for chronic hepatitis B, it's not the only option. Alternatives like Tenofovir Disoproxil Fumarate, Entecavir, and Lamivudine can effectively suppress the virus, and several are available as affordable generics.
The best alternative for you depends on your specific medical situation, so this is a decision to make with your doctor — not on your own. In the meantime, use Medfinder to search for Tenofovir Alafenamide availability near you, and explore our posts on the latest shortage updates and ways to save money on your prescription.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.